Navigation Links
Increased Usage of Mifeprex(R) Helps Slow Decline in Abortion Providers
Date:1/17/2008

~80% of Clinics Now Offer Mifeprex(R)

NEW YORK, Jan. 17 /PRNewswire/ -- The Guttmacher Institute announced today that use of Mifeprex(R) (the brand name for mifepristone) for early medication abortion increased substantially between 2000 and 2005. According to the report, approximately 78-81% of clinics now offer Mifeprex(R). The report also found that more than half of all known abortion providers are offering Mifeprex(R), a 70% increase from the first half of 2001. Additionally, these findings show that the increased number of Mifeprex(R) providers has helped to slow the overall decline in abortion providers. Since FDA approval of Mifeprex(R) in September 2000, more than 840,000 women in the United States have chosen Mifeprex(R) as a safe and effective, private option for ending early pregnancy.

Nearly 90% of abortions in the U.S. occur during the first trimester. In more recent years women having an abortion are able to do so earlier and earlier in the first trimester. According to Guttmacher, the proportion of providers offering very early medication or surgical abortions grew from 7% in 1993 to 40% in 2005. Mifeprex(R) allows women to act early, up to 7 weeks from the beginning of their last menstrual period. Currently, more than six in 10 abortions occur within the first 8 weeks of pregnancy.

Serious and sometimes fatal infections and bleeding occur very rarely following spontaneous, surgical, and medical abortions, including following Mifeprex(R) use. No causal relationship between the use of Mifeprex(R) and misoprostol and these events has been established. A high index of suspicion is needed to rule out serious and rarely fatal infections (e.g. Clostridium sordellii) and sepsis that can present without fever, bacteremia or significant findings on a pelvic exam, with or without abdominal pain, but with leukocytosis with a marked left shift, tachycardia, hemoconcentration, and general malaise.

Danco Laboratories, LLC is a women's health pharmaceutical company that has been granted an exclusive license from the Population Council to manufacture, market and distribute Mifeprex(R) in the United States.

For Prescribing Information, or more information about Mifeprex(R), please access the Mifeprex(R) web site at http://www.earlyoptionpill.com. Or call the Mifeprex(R) hotline at 1-877-4 Early Option (1-877-432-7596).

The Guttmacher Institute's study, "Abortion in the United States: Incidence and Access to Services, 2005" is the most complete available data on the number of abortions and abortion providers in the U.S.

Media Contact:

Mendy Andresen

206-332-1742


'/>"/>
SOURCE Danco Laboratories, LLC
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Increased distance to physician associated with thicker skin cancer at diagnosis
2. Methamphetamine study suggests increased risk for HIV transmission
3. New Alzheimers findings: High stress and genetic risk factor lead to increased memory decline
4. Minorities more likely to have sleep durations associated with increased mortality
5. Teens who see more smoking in movies may have increased risk of becoming established smokers
6. Study shows adverse drug events reported to the FDA have significantly increased
7. New Case Study Details How an Illinois Hospital Created a Safe Lifting Team that Dramatically Reduced Injuries, Increased Staff Satisfaction
8. Maternal depression and controlling behavior associated with increased stress response in infants
9. BioProcessors Launches SimCell(TM) Services to Meet Increased Customer Demand
10. Both short and long sleep is associated with increased mortality
11. New Study Shows Lower Costs, Increased Consumer Engagement in Account-Based Health Plans
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... McLean, Virginia (PRWEB) , ... April 24, 2017 ... ... have announced that they are seeking public support to bring their novel lifesaving ... in appearance, wearable device packed with medical-grade sensors, specially designed to read a ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... telehealth industry, announces the company’s VideoMedicine mobile platform has launched Quick Care, a ... hours a day, Quick Care provides patients with the option to request and ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... opioid overdose deaths now claim the lives of 62 Americans each day.(1) Yet ... against drug manufacturers, distributors, pharmacies and prescribers by more than half.(2) Novus ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... recognize elevated anxiety levels in people with addiction who are served by MAP’s ... a biosensing wearable device that monitors heart and breath rates to identify anxiety ...
(Date:4/24/2017)... Boston, MA (PRWEB) , ... April 24, 2017 ... ... the cardiovascular health of individuals with HIV because it is not known to ... statins may have favorable effects to both lower cholesterol levels and dampen inflammation ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), a ... Urology, Uro/Gyn and Gynecology markets with innovative and ... joined the Company as Senior Vice President, Marketing ... Mr. Keswani will report directly to Darin ... organization is delighted that Ash has joined the ...
(Date:4/20/2017)... April 20, 2017 Research and Markets has ... Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage of ... ... delivery technologies will rise from USD 20 Billion in 2015 to ... Drug Delivery Technologies - Innovation Driven by Rapidly Expanding Injectables Market ...
(Date:4/20/2017)... -- Eyevensys, a private biotechnology company developing ... technology that enables the safe, local, sustained production of ... range of ophthalmic diseases, announces it has received approval ... (MHRA) to advance its technology into clinical development. ... The EyeCET platform ...
Breaking Medicine Technology: